Related Experiment Video
Updated: Jul 1, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
[Low dose-intensity docetaxel monotherapy for patients with anthracycline-resistant metastatic breast cancer in poor
Zhi-Fang Liu1, Xi-Qin Zhang, Qi-Sen Guo
1Department of Medical Oncology, Shandong Cancer Hospital & Institute, Jinan 250117, China. lzhifang@gmail.com
Objective:
To evaluate the efficacy and safety of a weekly schedule of low dose-intensity docetaxel monochemotherapy for patients with anthracycline-resistant metastatic breast cancer (MBC) in poor physical status.
Methods:
Thirty MBC patients who were previously exposed to anthracycline treatment received docetaxel alone at a dose of 30 mg/m2 on D1, D8 and D15, repeated every 4 weeks for a maximum of 6 cycles.
Results:
Of the 30 evaluable patients, 2 (6.7%) achieved a complete response, and 9 (30.0%) a partial response, with an overall objective response rate of 36.7% (95% CI: 20.5%-53.9%). The most common adverse event was hematologic toxicity. After an average follow-up of 15.0 months, the median time to progression (TTP) was 8. 5 months and the median overall survival (OS) had not reached yet at the end of follow-up.
Conclusion:
The weekly low dose-intensity docetaxel monochemotherapy is effective and well-tolerated in patients with anthracycline-resistant metastatic breast cancer in poor physical status.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Drugs that Stabilize Microtubules
Drug Dosing: Obese Patients
Drugs that Destabilize Microtubules
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
